Beta test our new site.
|
Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | September 27, 2005 | ||||
Last Updated Date | June 24, 2010 | ||||
Start Date ICMJE | September 2005 | ||||
Primary Completion Date | November 2007 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Determine dosing range [ Time Frame: 25 weeks ] [ Designated as safety issue: Yes ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT00228436 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE | |||||
Original Secondary Outcome Measures ICMJE | |||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Safety, PD & PK of Multiple Doses of Hematide™ Injections for Anemia in Chronic Kidney Disease Patients | ||||
Official Title ICMJE | A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of Subcutaneously Administered Hematide™ Injection in Chronic Kidney Disease Patients Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment | ||||
Brief Summary | The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of Hematide in patients with chronic kidney disease (CKD) not hemodialysis who have not received ESA treatment |
||||
Detailed Description | |||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 2 | ||||
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Drug: Hematide™
Injection |
||||
Study Arms | |||||
Publications * | Macdougall IC, Wiecek A, Tucker B, Yaqoob M, Mikhail A, Nowicki M, MacPhee I, Mysliwiec M, Smolenski O, Sułowicz W, Mayo M, Francisco C, Polu KR, Schatz PJ, Duliege AM. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol. 2011 Nov;6(11):2579-86. Epub 2011 Sep 22. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Estimated Enrollment ICMJE | 60 | ||||
Completion Date | November 2007 | ||||
Primary Completion Date | November 2007 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 80 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | Poland, United Kingdom | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00228436 | ||||
Other Study ID Numbers ICMJE | AFX01-04 | ||||
Has Data Monitoring Committee | |||||
Responsible Party | Chief Medical Officer, Affymax | ||||
Study Sponsor ICMJE | Affymax | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Affymax | ||||
Verification Date | June 2010 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |